Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 273-281

  Moilanen, Jarna ^a   Lassus, Heini ^a   Leminen, Arto ^a   Vaheri, Antti ^b   Bützow, Ralf ^a   Carpén, Olli ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Ezrin; Immunohistochemistry; Multivariate analysis; Ovarian carcinoma; Serous carcinoma; Survival

Indexed keywords

EZRIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASTROCYTOMA; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; EPITHELIUM; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; UVEA MELANOMA;

EID: 0042624919     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00262-2     Document Type: Article

References (35)

1. Friedlander M.L. Prognostic factors in ovarian cancer. Semin Oncol. 25:1998;305-314.
2. Milner B.J., Allan L.A., Eccles D.M., Kitchener H.C., Leonard R.C., Kelly K.F., et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53:1993;2128-2132.
3. Enomoto T., Weghorst C.M., Inoue M., Tanizawa O., Rice J.M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 139:1991;777-785.
4. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58:1998;2095-2097.
5. Tapper J., Bützow R., Wahlström T., Seppäla M., Knuutila S. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer. 75:1997;1782-1787.
6. Ono K., Tanaka T., Tsunoda T., Kitahara O., Kihara C., Okamoto A., et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 60:2000;5007-5011.
7. Vaheri A., Carpén O., Heiska L., Helander T.S., Jääskelainen J., Majander-Nordenswan P., et al. The ezrin protein family membrane-cytoskeleton interactions and disease associations . Curr Opin Cell Biol. 9:1997;659-666.
8. Bretscher A., Chambers D., Nguyen R., Reczek D. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu Rev Cell Dev Biol. 16:2000;113-143.
9. Gautreau A., Poullet P., Louvard D., Arpin M. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Nat Acad Sci USA. 96:1999;7300-7305.
10. Dransfield D.T., Bradford A.J., Smith J., Martin M., Roy C., Mangeat P.H., Goldenring J.R. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J. 16:1997;35-43.
11. Mackay D.J., Esch F., Furthmayr H., Hall A. Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts an essential role for ezrin/radixin/moesin proteins . J Cell Biol. 138:1997;927-938.
12. Geiger K.D., Stoldt P., Schlote W., Derouiche A. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol. 157:2000;1785-1793.
13. Mäkitie T., Carpén O., Vaheri A., Kivelä T. Ezrin as a prognostic indicator and its relationship to tumor characteristics in malignant uveal melanoma. Inv Oft Vis Sci. 42:2001;2442-2449.
14. Khanna C., Khan J., Nguyen P., Prehn J., Caylor J., Yeung C., et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 61:2001;3750-3759.
15. Chen Z., Fadiel A., Feng Y., Ohtani K., Rutherford T., Naftolin F. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1 alpha and epidermal growth factor. Cancer. 92:2001;3068-3075.
16. Ohtani K., Sakamoto H., Rutherford T., Chen Z., Kikuchi A., Yamamoto T., et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett. 179:2002;79-86.
17. Fazioli F., Wong W.T., Ullrich S.J., Sakaguchi K., Appella E., Di Fiore P.P. The ezrin-like family of tyrosine kinase substrates receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation . Oncogene. 8:1993;1335-1345.
18. Kaul S.C., Mitsui Y., Komatsu Y., Reddel R.R., Wadhwa R. A highly expressed 81 kDa protein in immortalized mouse fibroblast its proliferative function and identity with ezrin . Oncogene. 13:1996;1231-1237.
19. Akisawa N., Nishimori I., Iwamura T., Onishi S., Hollingsworth M.A. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Comm. 258:1999;395-400.
20. Ohtani K., Sakamoto H., Rutherford T., Chen Z., Satoh K., Naftolin F. Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett. 147:1999;31-38.
21. Parlato S., Giammarioli A.M., Logozzi M., Lozupone F., Matarrese P., Luciani F., et al. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes a novel regulatory mechanism of the CD95 apoptotic pathway . EMBO J. 19:2000;5123-5134.
22. Helander T.S., Carpén O., Turunen O., Kovanen P.E., Vaheri A., Timonen T. ICAM-2 redistributed by ezrin as a target for killer cells. Nature. 382:1996;265-268.
23. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumors, No. 9. Geneva: WHO: 1973, p. 17-54.
24. International Federation of Gynecology and Obstetrics (FIGO) Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:263-4.
25. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:1998;844-847.
26. Böhling T., Turunen O., Jääskelainen J., Carpén O., Sainio M., Wahlström T., et al. Ezrin expression in stromal cells of capillary hemangioblastoma. An immunohistochemical survey of brain tumors. Am J Pathol. 148:1996;367-373.
27. SAGE databases ( http://www.ncbi.nlm.nih.gov/SAGE/ ).
28. Tokunou M., Niki T., Saitoh Y., Jmamura H., Sakamoto M., Hirohashi S. Altered expression of the ERM proteins in lung adenocarcinoma. Lab Invest. 80:2000;1643-1650.
29. Wiechen K., Diatchenko L., Agoulnik A., Scharff K.M., Schober H., Arlt K., et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 159:2001;1635-1643.
30. Majander-Nordenswan P., Sainio M., Turunen O., Jääskeläinen J., Carpén O., Kere J., et al. Genomic structure of the human ezrin gene. Human Genet. 103:1998;662-665.
31. Kiechle M., Jacobsen A., Schwarz-Boeger U., Hedderich J., Pfisterer J., Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer. 91:2001;534-540.
32. Shridhar V., Lee J., Pandita A., Iturria S., Avula R., Staub J., et al. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res. 61:2001;5895-5904.
33. Wang V.W., Bell D.A., Berkowitz R.S., Mok S.C. Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors. Cancer Res. 61:2001;4169-4174.
34. Crepaldi T., Gautreau A., Comoglio P.M., Louvard D., Arpin M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol. 138:1997;423-434.
35. Gautreau A., Louvard D., Arpin M. Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol. 150:2000;193-203.